Prediction of 90-day mortality among sepsis patients based on a nomogram integrating diverse clinical indices

Qing-Bo Zeng  
the 908th Hospital of Chinese PLA Logistical Support Force  
https://orcid.org/0000-0002-0742-125X

Long-Ping He  
the 908th Hospital of Chinese PLA Logistical Support Force

Nian-Qing Zhang  
Nanchang Hongdou Hospital of TCM

Qing-Wei Lin  
the 908th Hospital of Chinese PLA Logistical Support Force

Lin-Cui Zhong  
the 908th Hospital of Chinese PLA Logistical Support Force

Jing-Chun Song  
(songjingchun@126.com)  
the 908th Hospital of Chinese PLA Logistical Support Force  
https://orcid.org/0000-0001-5869-5077

Research

Keywords: Sepsis, Mortality, Nomogram, Prediction, Lactate

DOI: https://doi.org/10.21203/rs.3.rs-596906/v1

License: ☺ ☀ This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background

Sepsis is prevalent among intensive care units and is a frequent cause of death. Several studies have identified individual risk factors or potential predictors of sepsis-associated mortality, without defining an integrated predictive model. The present work aimed to define a nomogram for reliably predicting mortality.

Methods

We carried out a retrospective, single-center study based on 231 patients with sepsis who were admitted to our intensive care unit between May 2018 and October 2020. Patients were randomly split into training and validation cohorts. In the training cohort, multivariate logistic regression and a stepwise algorithm were performed to identify risk factors, which were then integrated into a predictive nomogram. Nomogram performance was assessed against the training and validation cohorts based on the area under receiver operating characteristic curves (AUC), calibration plots and decision curve analysis.

Results

Among the 161 patients in the training cohort and 70 patients in the validation cohort, 90-day mortality was 31.6%. Older age and higher values for the international normalized ratio, lactate level, and thrombomodulin level were associated with greater risk of 90-day mortality. The nomogram showed an AUC of 0.810 (95% CI 0.739 to 0.881) in the training cohort and 0.813 (95% CI 0.708 to 0.917) in the validation cohort. The nomogram also performed well based on the calibration curve and decision curve analysis.

Conclusion

This nomogram may help identify sepsis patients at elevated risk of 90-day mortality, which may help clinicians allocate resources appropriately to improve patient outcomes.

Introduction

Sepsis is life-threatening organ dysfunction initiated by the body's overwhelming response to infection [1]. Although significant advances have been made in intensive care and supportive technology to treat sepsis, it remains associated with high morbidity and mortality. The global incidence rate is around 437 per 100 000 person-years, and approximately 17% of sepsis cases die in hospital [2]. These figures are even higher in China, where up to 20% of patients in intensive care units have sepsis [3].
The pathogenesis of sepsis is complex and involves coagulation disorder, inflammation imbalance, immune dysfunction, as well as mitochondrial and endothelial damage [4]. Better understanding of the disease's pathophysiology and identification of reliable predictors of short-term mortality are critical for guiding interventions and improving prognosis.

Several studies have analyzed risk factors of mortality in patients with sepsis [5–9], but most have focused on biomarkers related to inflammation or the function of certain organs. For such a complex disease, prediction algorithms may need to take a range of biomarkers into account. Therefore, the main objective of the present study was to consider a diversity of potential clinicodemographic factors for constructing a nomogram to predict 90-day mortality in sepsis.

**Methods**

**Patients**

This retrospective study examined electronic medical record from a consecutive sample of 231 patients who had been diagnosed with sepsis and had been admitted to the intensive care unit at the 908th People's Liberation Army Hospital (Nanchang, China) between May 2018 and October 2020. To be enrolled in the study, patients had to be older than 17 years and diagnosed with sepsis according to the Third International Consensus Definition for Sepsis (“Sepsis-3”) [10]: infection had to be confirmed through culture tests, and the Sequential Organ Failure Assessment (SOFA) score had to be at least 2 [4]. Patients were excluded if they were pregnant or had a history of hemorrhagic shock, cancer, acute coronary syndrome, or cardiopulmonary arrest. This study was approved by the Ethics Committee of the 908th People's Liberation Army Hospital with a waiver of informed consent.

**Data collection**

Baseline demographic data (age, sex) were collected, as were data on the site of infection; comorbidities; 90-day mortality; severity of illness, based on Acute Physiology and Chronic Health Evaluation II (APACHE II) score [11] and the SOFA scores [12] on the first day of admission to the intensive care unit; as well as numerous laboratory and clinical variables (see Table 1).

**Statistical analysis and nomogram construction**

All statistical analyses were performed using R 4.0.1 (R Core Team, Vienna, Austria) and SPSS 25.0 (IBM, Chicago, IL, USA). Differences associated with a two-sided $P < 0.05$ were considered statistically significant.

Data for continuous variables were presented as mean ± standard deviation, or as median [interquartile range (IQR)]. Differences between groups were assessed for significance using Student’s t-test in the case of normally distributed data, or using the Mann-Whitney test in the case of a skewed distribution. Data for categorical variables were expressed as counts and percentages, and differences were assessed using $\chi^2$-test.
or Fisher's exact test. The variance inflation factor (VIF) was used to test collinearity between continuous variables, and an arithmetic square root of $VIF \leq 10$ was regarded as non-collinearity.

Patients were randomized into training and validation cohorts in a ratio of 2:1. Clinical variables in the training cohort were entered into multivariate logistic regression, and backward stepwise selection was applied using the likelihood ratio test and Akaike's information criterion as the stopping rule [13]. The regression results from the training cohort were used to define a nomogram to predict 90-day mortality. The same regression equations for the training cohort were also applied to the data for the validation cohort in order to verify the nomogram.

**Nomogram assessment**

Calibration curves, accompanied by the Hosmer-Lemeshow test, were used to evaluate the predictive model. Its discriminative ability was assessed based on the area under the receiver operating characteristic curve (AUC) [31]. For clinical usefulness, net benefit was examined against the training and validation cohorts using decision curve analysis (DCA).

**Results**

**Patient characteristics**

Among the 231 patients in the study, 61.9% were men, median age was 70 years (range, 18 to 96 years), and 73 (31.6%) died within 90 days of follow-up. In both the training and validation cohorts, patients who survived for 90 days had significantly lower levels of many clinical variables than those who died (Table 1), including tissue plasminogen activator-inhibitor complex, hrombin-antithrombin complex, prothrombin time, international normalized ratio, activated partial thrombin time, thrombin time, fibrinogen degradation product, D-dimer, Creatinine, lactate, Heartrate, Sequential Organ Failure Assessment, Acute Physiology and Chronic Health Evaluation II. Conversely, survivors showed significantly higher levels of Platelet, hemoglobin, and arterial partial oxygen pressure.
## Table 1
Patient characteristics upon admission to the intensive care unit

| Characteristic                  | Training cohort                  | Validation cohort                  |
|--------------------------------|----------------------------------|------------------------------------|
|                                | Survivors (n = 112) | Died at 90 days (n = 49) | P value | Survivors (n = 46) | Died at 90 days (n = 24) | P value |
|--------------------------------|-------------------------|-----------------------------------|----------|-------------------|------------------------|----------|
| Men                            | 69 (61.6)               | 30 (61.2)                         | 0.963    | 29 (63.0)         | 15 (62.5)              | 0.964    |
| Age ≥ 57 yr                     | 47 (42.0)               | 32 (65.3)                         | 0.006    | 30 (65.2)         | 22 (91.7)              | 0.016    |
| Comorbidity                     |                         |                                   |          |                   |                        |          |
| Diabetes                        | 17 (15.2)               | 10 (20.4)                         | 0.414    | 17 (37.0)         | 9 (37.5)               | 0.964    |
| Hypertension                    | 42 (37.5)               | 26 (53.1)                         | 0.066    | 21 (45.7)         | 12 (50.0)              | 0.729    |
| COPD                            | 6 (5.4)                 | 6 (12.2)                          | 0.126    | 8 (17.4)          | 6 (25.0)               | 0.450    |
| CKD                             | 10 (8.9)                | 6 (12.2)                          | 0.518    | 2 (4.3)           | 3 (12.5)               | 0.209    |
| Source of infection             |                         |                                   |          |                   |                        |          |
| Pulmonary                       | 71 (63.4)               | 33 (67.3)                         | 0.629    | 27 (58.7)         | 19 (71.2)              | 0.087    |
| Urinary tract                   | 8 (7.1)                 | 1 (2.0)                           | 0.195    | 5 (10.9)          | 0 (0)                  | 0.094    |
| Abdominal                       | 27 (24.1)               | 14 (28.6)                         | 0.550    | 13 (28.3)         | 3 (12.5)               | 0.136    |
| Skin                            | 6 (5.4)                 | 2 (4.1)                           | 0.732    | 2 (4.3)           | 1 (4.2)                | 0.972    |
| TM ≥ 13.1 TU/mL                 | 17 (15.2)               | 22 (44.9)                         | 0.000    | 17 (37.0)         | 17 (70.8)              | 0.007    |
| TAT, ng/ml                      | 8.2 (4.6–18.0)          | 17.2 (5.7–46.8)                   | 0.002    | 8.7 (5.6–17.0)    | 13.4 (6.2–30.9)        | 0.162    |
| PIC, ug/mL                      | 1.16 (0.62–2.16)        | 1.04 (0.57–2.28)                  | 0.742    | 1.10 (0.75–1.48)  | 1.43 (0.69–2.83)        | 0.421    |
| t-PAIC, ng/ml                   | 12.2 (7.6–24.1)         | 21.7 (11.3–41.7)                  | 0.003    | 14.2 (9.4–23.9)   | 21.3 (13.8–47.1)        | 0.020    |

Values are n (%), mean ± SD or median (interquartile range).

COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; TM, thrombomodulin; TAT, thrombin-antithrombin complex; PIC α2-plasmininhibitor-plasmin complex, tPAIC tissue plasminogen activator-inhibitor complex, PLT Platelet, HB hemoglobin, PT prothrombin time, APTT activated partial thrombin time, FIB fibrinogen, INR international normalized ratio, TT thrombin time, FDP fibrinogen degradation product, ALT alanine transaminase, AST aspartate transaminase, TBil total bilirubin, MAP mean arterial pressure, SOFA Sequential Organ Failure Assessment, APACHE II Acute Physiology and Chronic Health Evaluation II, PH potential of hydrogen, PaO₂ arterial partial oxygen pressure, PaCO₂ arterial partial pressure of carbon dioxide, Lac lactate.
| Characteristic | Training cohort | Validation cohort |  |
|---------------|-----------------|-------------------|---|
|               | Survivors (n = 112) | Died at 90 days (n = 49) | P value | Survivors (n = 46) | Died at 90 days (n = 24) | P value |
| PT, s         | 14.2 (12.7–16.2) | 16.4 (14.0–21.4) | 0.000 | 13.7 (13.5–15.3) | 15 (13.6–19.6) | 0.008 |
| INR           | 1.2 (1.1–1.3) | 1.4 (1.2–1.8) | 0.000 | 1.14 (1.08–1.27) | 1.25 (1.13–1.60) | 0.008 |
| APTT, s       | 31.6 (26.6–38.4) | 37.4 (32.0–47.7) | 0.000 | 31.4 (26.7–40.5) | 33.9 (29.2–48.7) | 0.087 |
| FIB, s        | 2.9 ± 1.09 | 2.6 ± 1.2 | 0.143 | 2.9 ± 0.9 | 2.7 ± 1.3 | 0.308 |
| TT, s         | 15.8 (14.5–17.3) | 17.2 (14.8–18.7) | 0.003 | 15.5 (14.0–17.4) | 16.8 (14.9–19.4) | 0.070 |
| FDP, µg/L     | 8.69 (3.67–18.92) | 14.45 (4.53–38.00) | 0.030 | 7.56 (4.51–13.12) | 11.37 (6.99–27.95) | 0.033 |
| D-dimer, µg/L | 2.59 (1.03–5.97) | 4.91 (1.65–11.00) | 0.016 | 2.19 (0.87–4.53) | 3.19 (2.54–7.76) | 0.015 |
| Platelets, ×10^9/L | 179 ± 90 | 138 ± 94 | 0.010 | 182 ± 108 | 209 ± 128 | 0.358 |
| Hemoglobin, g/L | 111 ± 29 | 100 ± 31 | 0.038 | 109 ± 31 | 104 ± 31 | 0.525 |
| ALT, U/L      | 31.9 (12.9–73.5) | 21.5 (13.3–116.8) | 0.597 | 27.3 (13.3–58.7) | 29.6 (11.1–64.2) | 0.921 |
| AST, U/L      | 43.0 (23.3–84.3) | 42.1 (26.4–131.2) | 0.483 | 33.2 (19.8–72.5) | 30.3 (19.1–76.7) | 0.843 |
| TBil, µmol/L  | 13.5 (7.9–22.5) | 13.9 (7.4–32.5) | 0.514 | 14.5 (6.8–23.4) | 17.6 (10.9–28.1) | 0.192 |
| Cr, µmol/ml   | 92.6 (62.3–163.8) | 136 (76.5–241.4) | 0.017 | 70.3 (54.5–132.5) | 113.4 (78.3–150.0) | 0.056 |

Values are n (%), mean ± SD or median (interquartile range).

COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; TM, thrombomodulin; TAT, thrombin-antithrombin complex; PIC α2-plasmin inhibitor-plasmin complex, tPAIC tissue plasminogen activator-inhibitor complex, PLT Platelet, HB hemoglobin, PT prothrombin time, APTT activated partial thrombin time, FIB fibrinogen, INR international normalized ratio, TT thrombin time, FDP fibrinogen degradation product, ALT alanine transaminase, AST aspartate transaminase, TBil total bilirubin, MAP mean arterial pressure, SOFA Sequential Organ Failure Assessment, APACHE II Acute Physiology and Chronic Health Evaluation II, PH potential of hydrogen, PaO2 arterial partial oxygen pressure, PaCO2 arterial partial pressure of carbon dioxide, Lac lactate.
| Characteristic       | Training cohort                                                                 | Validation cohort                                                                 |
|---------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
|                     | Survivors (n = 112)                                                              | Survivors (n = 46)                                                               |
|                     | Died at 90 days (n = 49)                                                         | Died at 90 days (n = 24)                                                         |
| P value             |                                                                                  |                                                                                  |
| Body temp, °C       | 36.7 (36.5–37.5)                                                                 | 36.7 (36.2–37.3)                                                                 |
|                     | 36.6 (36.3–37.3)                                                                 | 36.4 (36.0–36.8)                                                                 |
| Heart rate, min⁻¹   | 96 ± 20                                                                          | 98 ± 26                                                                          |
|                     | 106 ± 25                                                                         | 107 ± 26                                                                         |
| MAP, mmHg           | 90 ± 17                                                                          | 91 ± 17                                                                          |
|                     | 88 ± 22                                                                          | 87 ± 18                                                                          |
| SOFA score          | 7 (5–10)                                                                         | 7 (5–10)                                                                         |
|                     | 9 (7–15)                                                                         | 9 (6–13)                                                                         |
| APACHE II score     | 21 ± 6                                                                           | 22 ± 7                                                                           |
|                     | 24 ± 6                                                                           | 27 ± 7                                                                           |
| PH                  | 7.41 (7.35–7.45)                                                                 | 7.42 (7.34–7.49)                                                                 |
|                     | 7.38 (7.29–7.50)                                                                 | 7.29 (7.19–7.43)                                                                 |
| PaCO₂, mmHg         | 36 (31–42)                                                                       | 34 (28–41)                                                                       |
|                     | 34 (29–40)                                                                       | 39 (32–46)                                                                       |
| PaO₂, mmHg          | 110 (81–157)                                                                     | 112 (80–167)                                                                     |
|                     | 93 (64–140)                                                                       | 97.1 (64–152)                                                                    |
| Lac, mmol/L         | 1.7 (1.3–2.2)                                                                    | 3.2 (1.5–6.6)                                                                    |
|                     |                                                                                  | 2.0 (1.2–3.3)                                                                    |
|                     |                                                                                  | 3.8 (1.8–9.5)                                                                    |
|                     | 0.000                                                                            | 0.000                                                                            |
|                     | 0.017                                                                            | 0.366                                                                            |
|                     | 0.017                                                                            | 0.010                                                                            |

Values are n (%), mean ± SD or median (interquartile range).

COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; TM, thrombomodulin; TAT, thrombin-antithrombin complex, PIC α2-plasmin inhibitor-plasmin complex, tPAIC tissue plasminogen activator-inhibitor complex, PLT Platelet, HB hemoglobin, PT prothrombin time, APTT activated partial thrombin time, FIB fibrinogen, INR international normalized ratio, TT thrombin time, FDP fibrinogen degradation product, ALT alanine transaminase, AST aspartate transaminase, TBil total bilirubin, MAP mean arterial pressure, SOFA Sequential Organ Failure Assessment, APACHE II Acute Physiology and Chronic Health Evaluation II, PH potential of hydrogen, PaO₂ arterial partial oxygen pressure, PaCO₂ arterial partial pressure of carbon dioxide, Lac lactate.

**Nomogram construction**

Multiple logistic regression identified age, international normalized ratio, lactate, and thrombomodulin as independent predictors of 90-day mortality (Table 2), which were then integrated into a predictive nomogram (Fig. 1).
Table 2
Multivariate logistic regression of data from the training cohort to identify factors independently associated with 90-day mortality

| Variable                      | Odds ratio | 95% confidence interval | P value |
|------------------------------|------------|-------------------------|---------|
| Age (≥ 57 vs.<57 y)          | 1.20       | 0.36–2.04               | 0.005   |
| TM (≥ 13.1 vs. <13.1 TU/mL)  | 1.30       | 0.39–2.21               | 0.005   |
| INR                          | 1.52       | 0.23–2.80               | 0.021   |
| Lac (mmol/L)                 | 0.17       | 0.04–0.29               | 0.008   |

INR international normalized ratio, TM thrombomodulin, Lac lactate

Nomogram validation

The nomogram based on data in the training cohort gave an AUC of 0.810 (95% CI 0.739 to 0.881) for predicting 90-day mortality in that cohort (Fig. 2A). Similarly, it gave an AUC of 0.813 (95% CI 0.708 to 0.917) for predicting 90-day mortality in the validation cohort (Fig. 2B).

For both cohorts, the nomogram should good agreement with actual 90-day mortality based on calibration curves (Fig. 3), although the logistic calibration curve and nonparametric curve deviated slightly from the ideal line. The Hosmer-Lemeshow test gave a p = 0.866 in the training cohort while p = 0.801 in the validation cohort, suggesting no significant deviation from a perfect fit.

Potential clinical usefulness of the nomogram

DCA showed good clinical potential for the nomogram, based on the training cohort (Fig. 4A) and validation cohort (Fig. 4B). When the threshold probability is greater than 15%, using the nomogram can lead to lower mortality than treating either all or none of the patients.

Discussion

In this study, we defined a nomogram based on routinely measured clinical variables that may reliably predict 90-day mortality among patients with sepsis. While our nomogram should be verified with other patient populations, it establishes the feasibility of accurate mortality prediction using relatively simple clinical tests. While several studies have identified risk factors associated with 90-day mortality in sepsis, our work suggests that certain risk factors may be particularly relevant for screening patients for mortality risk.

The 90-day mortality in our retrospective cohort of Chinese patients was 31.6%, which was higher than in previous studies [2, 3, 5]. Sepsis patients concluded in the present study had much higher APACHE II scores and had a longer follow-up (90-day mortality) than in previous reports, which could make an explanation of these differences[14].
We found that international normalized ratio was significantly higher among sepsis patients who died within 90 days of follow-up than among those who did not die, and it emerged as an independent predictor of 90-day mortality in multivariate analysis. Coagulopathy is frequently observed in sepsis [15], and it contributes to multiple organ dysfunction syndrome [16]. More severe coagulopathy has been linked to higher risk of mortality among patients with sepsis [17], and clinical parameters reflecting hemostasis can predict sepsis-related mortality [18–20]. Our results are consistent with this literature. Nevertheless, international normalized ratio alone cannot accurately predict sepsis outcomes [5], which our results suggest may be due to the need to take into account other independent predictors of mortality.

One of those predictors is lactate level, which was significantly higher among our patients who died within 90 days than among those who did not. Critically ill patients, particularly those with sepsis or septic shock, show elevated lactate [21], and the magnitude of the elevation correlates strongly and positively with sepsis severity and associated mortality [22–24]. Serum lactate levels are considered a marker of tissue hypoxia [19], and they have proven useful for guiding clinical treatment and predicting prognosis in various clinical contexts [25]. Our study supports the “Sepsis 3” recommendation that septic shock be defined as persistence of serum lactate > 2 mmol/L [10].

Another risk factor of 90-day mortality that emerged as particularly important for prediction was elevated thrombomodulin level. Thrombomodulin, an integral endothelial cell membrane protein, is cleaved and released into the bloodstream during sepsis and septic shock [26, 27], leading to elevated levels of serum thrombomodulin in pediatric and adult sepsis patients [28, 29]. Endothelium is the primary site of damage in sepsis due to massive production of proinflammatory cytokines [30]. Elevated serum thrombomodulin level is associated with sepsis severity and risk of death [31].

Our nomogram showed AUC values above 0.8 for the training and validation cohorts, suggesting good predictive ability. In addition, DCA suggested that treating our cohorts according to our nomogram's predictions could be superior to treating all or none of them. The calibration curve also suggested good fit. Nevertheless, our model was generated based on retrospective analysis of a relatively small sample from a single medical center, so it should be validated in other patient populations. It may be possible to further improve the model by a multicenter study with external validation.

**Conclusion**

We have developed a nomogram that may reliably predict 90-day mortality in patients with sepsis, based on age, international normalized ratio, lactate, and thrombomodulin. This may help clinicians identify patients at higher risk and modify clinical management and resource allocation accordingly.

**Abbreviations**

COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; TM: thrombomodulin; TAT: thrombin-antithrombin complex; PIC: α2-plasmininhibitor-plasmin complex; tPAIC: tissue plasminogen
Declarations

Acknowledgements

None

Authors’ contributions

QBZ, LPH and JCS designed this study. LPH collected the data. NQZ, LCZ and QWL were responsible for the statistical analysis. QBZ and LPH were the first writing authors of the manuscript. JCS finalized this manuscript. The authors read and approved the final manuscript.

Authors’ information

1. Intensive Care Unit the 908th Hospital of Chinese PLA Logistical Support Force Nanchang 330002 Jiangxi Province China. 2. Intensive Care Unit Nanchang Hongdou Hospital of TCM Nanchang 330002 Jiangxi Province China.

Funding

None

Availability of data and materials

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of all the study centers. Written informed consent was waived by the Ethics Commission of 908th hospital.

Competing interests

The authors declare that they have no competing interests.
Consent for publication

No individual participant data is reported that would require consent to publish from the participant.

References

1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit. Care Med. 2017; 45:486–552.

2. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimate and Limitations. Am J Respir Crit Care Med. 2016, 193(3):259-72.

3. Xie J, Wang H, Kang Y, Zhou L, Liu Z, Qin B, et al. The Epidemiology of Sepsis in Chinese ICUs: A National Cross-Sectional Survey. Crit. Care Med. 2020; 48(3):e209-e218.

4. Huang M, Cai S, Su J. The Pathogenesis of Sepsis and Potential Therapeutic Targets. Int J Mol Sci. 2019; 20(21):5376.

5. Liu J, Bai C, Li B, Shan A, Shi F, Yao C, et al. Mortality prediction using a novel combination of biomarkers in the first day of sepsis in intensive care units. Sci Rep. 2021; 11(1):1275.

6. Johansen ME, Johansson PI, Ostrowski SR, Bestle MH, Hein L, Jensen AL, et al. Profound endothelial damage predicts impending organ failure and death in sepsis. Semin Thromb Hemost. 2015; 41(1):16-25.

7. Wang M, Jiang L, Zhu B, Li W, Du B, Kang Y, et al. The Prevalence, Risk Factors, and Outcomes of Sepsis in Critically Ill Patients in China: A Multicenter Prospective Cohort Study. Front Med (Lausanne). 2020; 7:593808.

8. Bateman RM, Sharpe MD, Jagger JE, Ellis CG, Solé-Violán J, López-Rodríguez M, et al. Risk Factors for Mortality, Intensive Care Unit Admission, and Bacteremia in Patients Suspected of Sepsis at the Emergency Department: A Prospective Cohort Study. Open Forum Infect Dis. 2020; 8(1):ofaa594.

9. Innocenti F, Meo F, Giacomelli I, Tozzi C, Ralli ML, Donnini C, et al. Prognostic value of serial lactate levels in septic patients with and without shock. Intern. Emerg. Med. 2019; 14: 1321–30.

10. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8).

11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13:818–29.

12. Raith, E. P. et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017; 317: 290–300.

13. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. BMJ. 2015;350:
14. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014, 311(13):1308-16.

15. Perner A, Rhodes A, Venkatesh B, Angus DC, Martin-Loeches I, Preiser JC, et al. Sepsis: Frontiers in supportive care, organisation and research. Intensive Care Med. 2017; 43:496–508.

16. Lelubre, C. & Vincent, J. L. Mechanisms and treatment of organ failure in sepsis. Nat. Rev. Nephrol. 2018;14: 417–27.

17. Lyons PG, Micek ST, Hampton N, Kollef MH. Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality. Crit Care Med. 2018; 46(5):736-742.

18. Innocenti F, Gori AM, Giusti B, Tozzi C, Donnini C, Meo F, et al. Prognostic value of sepsis-induced coagulation abnormalities: an early assessment in the emergency department. Intern Emerg Med. 2019; 14(3):459-466.

19. Benediktsson S, Frigyesi A, Kander T. Routine coagulation tests on ICU admission are associated with mortality in sepsis: an observational study. Acta Anaesthesiol Scand. 2017;61(7):790-6.

20. Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017; 7(9):1-6.

21. Suetrong B, Walley KR. Lactic Acidosis in Sepsis: It’s Not All Anaerobic: Implications for Diagnosis and Management. Chest. 2016; 149(1):252-61.

22. Nolt B, Tu F, Wang X, Ha T, Winter R, Williams DL, et al. Lactate and Immunosuppression in Sepsis. Shock. 2018; 49(2):120-5.

23. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med. 2004; 32(8):1637-42.

24. Wacharasint P, Nakada TA, Boyd JH, Russell JA, Walley KR. Normal-range blood lactate concentration in septic shock is prognostic and predictive. Shock. 2012; 38(1):4–10.

25. Rishu AH, Khan R, Al-Dorzi HM, Tamim S, Al-Qahtani S, Al-Ghamdi G, et al. Even mild hyperlactatemia is associated with increased mortality in critically ill patients. Crit Care. 2013;17:R197.

26. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008; 83(3): 536–45.

27. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci US A. 1981;78(4):2249–2252.

28. Liu Z, Meng Z, Li Y, Zhao J, Wu S, Gou S, et al. Prognostic accuracy of the serum lactate level, the SOFA score and the qSOFA score for mortality among adults with Sepsis. Scand J Trauma Resusc Emerg Med. 2019; 27(1):51.
29. Lin JJ, Hsiao HJ, Chan OW, Wang Y, Hsia SH, Chiu CH. Increased serum thrombomodulin level is associated with disease severity and mortality in pediatric sepsis. PLoS One. 2017; 12(8):e0182324.

30. Johansen ME, Johansson PI, Ostrowski SR, Bestle MH, Hein L, Jensen AL, et al. Profound endothelial damage predicts impending organ failure and death in sepsis. Semin Thromb Hemost. 2015; 41(1):16-25.

31. Lin SM, Wang YM, Lin HC, Lee KY, Huang CD, Liu CY, et al. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med. 2008; 36(3):683-9.

**Figures**

![Nomogram for predicting 90-day mortality in patients with sepsis, based on data in the training cohort.](image)

**Figure 1**

Nomogram for predicting 90-day mortality in patients with sepsis, based on data in the training cohort.
Figure 2

Receiver operating characteristic curves assessing the ability of the nomogram to predict 90-day mortality in (A) training and (B) validation cohorts.

Figure 3
Calibration plot of predicted and observed probabilities of 90-day mortality in (A) training and (B) validation cohorts.

Figure 4

Decision curve analysis to assess the benefit of clinical intervention based on the predictive nomogram in (A) training and (B) validation cohorts.